Synexus acquires Research Across America
Tuesday, March 1, 2016
Synexus has purchased Research Across America for an undisclosed sum. Research Across America was founded by Dr. Jeffrey Adelglass and has proven clinical trial expertise, having conducted over 2000 clinical trials at its dedicated research sites.
Since being taken private in 2007, Synexus has enjoyed consistent growth using its targeted buy and build strategy. This has created a leading site management organization (SMO), dedicated to the recruitment and management of clinical trials across the globe. Synexus already owns 25 dedicated research sites across 10 countries. The addition of multiple new sites in the U.S. means that Synexus can now offer customers access to over 79 million potential patients. The deal provides important capacity, U.S. market expertise and therapeutic experience.
The Synexus dedicated site model of patient recruitment, trial conduct and patient retention improves the speed and efficiency of clinical trials on behalf of pharma, biotech and CRO customers. Dedicated sites benefit from its investment in best-in-class quality SOPs, access to scientific advisory boards for key therapeutic areas and a wide network of KOLs that provide valuable insight to customers. Its specialist tailored enrolment and retention strategies address a key challenge in the global clinical trial industry where almost 90% of all trials undertaken are delayed due to slow patient enrolment, leading to delayed access to new medicines for patients.
Speaking about the acquisition, Christophe Berthoux, CEO said, “Synexus already has a strong international footprint. This latest acquisition is an important one for Synexus as it marks our entry into the U.S. market, giving us truly global capability. We spent a great deal of time considering an appropriate partner and selected Research Across America as it has a number of synergies with the Synexus model. In addition by adding these sites to our network we have also gained expertise in areas, such as dermatology and generics, enabling us to further support our client base.”